by Maria Zannes | Oct 7, 2015 | Press Releases
OCTOBER 7, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, will seat two new members on its Board of Directors at the third-quarter meeting Oct. 26, 2015. Company President and Chief Executive Officer Maria Zannes...
by Maria Zannes | Oct 4, 2015 | News
OCTOBER 4, 2015 By Maria Zannes, President & Chief Executive Officer (SAN ANTONIO, TX ) Early detection of cancer prolongs life. Each of us at bioAffinity Technologies has seen this firsthand. Our brothers, sisters, parents, friends and patients, and many of us...
by Maria Zannes | Sep 30, 2015 | Press Releases
SEPTEMBER 30, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, today announced the renewal of its research collaboration with The University of Texas Health Science Center at San Antonio to optimize its patented CyPath®...
by Maria Zannes | Sep 23, 2015 | Press Releases
SEPTEMBER 23, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that results from a 128-patient proof-of-concept clinical study for its non-invasive and quantitative assay for early-stage lung cancer were...
by Dale Harrison | Sep 16, 2015 | Publications
“Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphine (TCPP)-Labeled Sputum” Journal of Thoracic Oncology, September, 2015 Authors L. Patriquin, MD, Radiology Assoc.; D. Merrick, MD, Denver VA Medical Center; D. Hill, MD,...
